Revolutionizing Cervical Cancer Screening: PHASiFY Technology Takes Spotlight at China National Conference

Shenzhen, March 2, 2025 — The "China Self-Sampling Cervical Cancer Screening Expert Symposium," jointly organized by the Chinese Society for Colposcopy and Cervical Pathology (CSCCP), the Gynecologic Oncology Branch of the Chinese Medical Association, the Fertility Protection Branch of the Chinese Preventive Medicine Association (CSFP), and the Fertility Protection Committee of the Chinese Anti-Cancer Association, was successfully held in Shenzhen. The event was co-hosted by the editorial office of the Chinese Journal of Clinical Obstetrics and Gynecology, the Gynecology and Obstetrics Committee of the Shenzhen Women Doctors Association, and Peking University Shenzhen Hospital. The symposium brought together top domestic and international experts, including Professor Wei Lihui, Academician Ma Ding, Professor Wu Ruifang, Professor Li Changzhong, and international expert Dr. Jerome L. Belinson, to discuss how technological innovation can drive the popularization and optimization of cervical cancer screening, contributing to the World Health Organization (WHO)'s global goal of "eliminating cervical cancer by 2030."

On-Site Photos from the China Self-Sampling Cervical Cancer Screening Expert Symposium
 

Professor Wang Linhong from Peking University People's Hospital Shares Insights at the Conference
 

Professor Wang Linhong from Peking University People's Hospital highlighted that, as of 2019, the cervical cancer screening coverage rate in China was 29.5% for women aged 20-64 and 36.8% for those aged 35-64. However, 64% of the population had never undergone cervical cancer screening, indicating a significant gap from the WHO's target of 70% screening coverage. The current state of cervical cancer screening in China faces substantial challenges.

Major Announcement: Groundbreaking Clinical Data Unveiled, Driving Screening Model Innovation

During the symposium's closed-door session, PHASE Scientific and Peking University Shenzhen Hospital jointly released breakthrough clinical data on the PHASiFY™ urine-based HPV detection technology. The clinical study (ChiCTR2300071041) revealed that the PHASiFY™-based urine HPV test achieved a sensitivity of 93.42% for detecting CIN2+ (including cervical precancerous lesions and invasive cervical cancer). This milestone validates the reliability and practicality of self-sampling urine technology in cervical cancer screening, providing scientific evidence for non-invasive screening methods.

Professor Li Changzhong, Director of the Obstetrics and Gynecology Department at Peking University Shenzhen Hospital, stated during the announcement: "The PHASiFY™ technology significantly enhances the sensitivity of urine-based HPV and methylation detection, offering broad application prospects. By efficiently concentrating viral DNA in urine, it addresses the industry pain point of insufficient sensitivity in traditional screening methods. It also improves screening rates in underserved areas, ethnic minority communities, and among individuals requiring HPV-positive follow-ups, providing a convenient and efficient screening option."

Professor Li Changzhong further revealed: "The results of this study were awarded the 'Outstanding Clinical Research Award' at the annual meeting of the American Society for Colposcopy and Cervical Pathology (ASCCP). The unique urine concentration technology (PHASiFY™) and its detection capabilities have generated significant interest and excitement within the academic community."

On-Site Photos of Professor Li Changzhong Sharing Insights at the Conference

PHASiFY™ Technology: Redefining Cervical Cancer Screening Globally
At the core of PHASiFY™ technology is its globally pioneering aqueous two-phase extraction system (ATPS), which can concentrate target analytes (such as HPV viral DNA) in urine and other samples by more than 10 times, significantly improving detection sensitivity. This breakthrough not only resolves the issue of sample quality instability in traditional screening but also provides a scientific foundation for at-home self-testing.
 

Dr. Ricky Chiu, Founder and CEO of PHASE Scientific, emphasized during the technology sharing session: "The development of PHASiFY™ technology has spanned over a decade. Its unique advantage lies in its ability to efficiently concentrate DNA from urine, blood, saliva, and other samples, significantly enhancing detection sensitivity. By extracting high-concentration samples, PHASiFY™ technology is not only applicable to cervical cancer screening but also to early cancer detection, infectious disease monitoring, and other fields of in vitro diagnostics. It offers more accurate, cost-effective, and faster feedback to users, truly fulfilling the purpose of 'early screening.'"

On-Site Photos of Dr. Ricky Chiu, Founder and CEO of PHASE Scientific Sharing Insights at the Conference
 

PHASiFY™ technology has been validated in multiple international clinical studies. Collaborative research with the MD Anderson Cancer Center in the U.S. demonstrated that its cell-free DNA (cfDNA) extraction efficiency is 3-4 times higher than traditional methods. Additionally, the technology has received support from authoritative institutions such as the U.S. National Science Foundation (NSF), the National Institutes of Health (NIH), and the Bill & Melinda Gates Foundation. It was also published in a Nature journal in 2021.

From Lab to Home: Technology Brings Health Services "Zero Distance"

Leveraging the groundbreaking advantages of PHASiFY™ technology, PHASE Scientific has launched the innovative INDICAID™ urine-based HPV self-sampling test. Users only need 20-40 milliliters of urine to complete precise genotyping of 23/27/49 HPV types, with a 98.5% consistency rate compared to hospital cervical swab sampling and an 80% improvement in screening efficiency.
 

For working women nowadays, this technology addresses core pain points such as "high time costs and privacy concerns." Users can avoid hospital queues by simply collecting a sample at home in 3 minutes and sending it via courier to receive a report with the same functionality as those from top-tier hospitals. In remote areas with limited medical resources, the non-invasive and at-home nature of PHASiFY™ technology not only protects women's privacy but also accommodates the cultural practices of certain ethnic minorities, holding profound social significance.
 

Clinical data shows that the HPV infection rate among adult men in China is as high as 20%-30%. Since the virus can be transmitted through sexual contact, male carriers can pose a potential health risk to their partners. However, traditional male HPV testing requires invasive sampling, leading to discomfort and low voluntary screening rates among men. Inadequate sampling can also significantly reduce test accuracy.
 

As a critical link in the HPV transmission chain, men's proactive screening is not only a responsibility for their own health but also a direct expression of care for their partners. With the widespread adoption of urine self-sampling technology, more men can easily participate in screening and proactive health management, building a stronger protective barrier for their partners.
 

Mr. Gary Guan, General Manager of PHASE Scientific China, emphasized in his speech: "The ultimate goal of technological innovation is to safeguard the health of every family. We are transitioning from 'single screening' to 'full-cycle protection.' In the future, PHASE Scientific will collaborate closely with top domestic and international experts and institutions, leveraging the unique advantages of PHASiFY™ technology, particularly in at-home testing scenarios such as urine self-sampling. We aim to provide non-invasive, convenient, and accurate early screening services for cervical cancer, bladder cancer, endometrial cancer, and other prevalent cancers globally. We will also expand into other high-incidence cancer areas such as colorectal, lung, and liver cancers, offering innovative solutions for public health management."
 

On-Site Interview with Mr. Gary Guan, General Manager of PHASE Scientific China
 

About PHASE Scientific International
PHASE Scientific International is an international biotechnology company dedicated to advancing cancer and infectious disease detection through innovative technologies. With a mission to "make innovative technologies accessible for health," the company focuses on developing breakthrough sample processing technologies. Its core patented PHASiFY™ technology has gained widespread recognition globally.